Editor’s Note: Regular Daily readers know we pounce on any chance we get to share timeless investing wisdom from Agora Inc.’s all-time best stock picker, Chris Mayer. Every $100,000 invested in Chris’ recommendations turned into $480,000 over 10 years. When he offers advice, we listen… Today Chris reveals the three signs he looks for when […]
From Nick Giambruno, senior editor, International Man: Do you really own something if the government forces you to make never-ending payments on it? I think the answer is “no.” You possess such an item, but you don’t own it outright. It’s an important distinction. A ridiculous threat to property rights has infected most of the world like a virus. Most people […]
Editor’s Note: We have something special to share with you today. In this brand-new commentary, Casey Research founder Doug Casey explains why Canada is headed for a self-inflicted disaster. This coming crisis could do serious damage to Canada’s economy. But it will be a “sideshow” compared to what’s about to hit the U.S. Fair warning: […]
From Bill Bonner, chairman, Bonner & Partners: Elizabeth received a strange letter from her congressman. “We have to be on guard against our enemies… and not be afraid to name them.” A brave, forthright stand? But wait, he didn’t name the enemies. Preposterous Lies That left us wondering: Who are our enemies? Muslims, Jews, Arabs… […]
From Chris Mayer, chief investment strategist, Bonner & Partners: Rankin Hodgins had humble beginnings… He was born in 1921 on a farm in Saskatchewan, Canada. He eventually went on to work in insurance and never made more than $65,000 per year. In 1978, he started investing in the stock market. He began with $200,000. He […]
Editor’s Note: Below we share the most valuable wealth-building insights we’ve found over the last week. We also offer you the chance to peruse the best-selling services in our industry. $ For the First Time Ever: Chris Mayer’s Seeking Readers to Try His Brand-New Investment Research Service Risk-Free. (Special Charter Offer: Buy One Year, Get One […]
It’s the stuff investors’ dreams are made of: Near 100% gains in about a month… Except if you’re a Palm Beach Confidential subscriber, those gains are yours to keep. On Monday, drugmaker Sarepta Therapeutics Inc. (SRPT) received Food and Drug Administration (FDA) approval for eteplirsen (a Duchenne muscular dystrophy drug). The stock rocketed up over […]